The First Report of Successful Carotid Stent Implant Using Argatroban Anticoagulation in a Patient with Heparin-Induced Thrombocytopenia and Thrombosis Syndrome
Restricted accessResearch articleFirst published online January, 1998
The First Report of Successful Carotid Stent Implant Using Argatroban Anticoagulation in a Patient with Heparin-Induced Thrombocytopenia and Thrombosis Syndrome
We report the first successful carotid stent implant in a patient with heparin-induced thrombocytopenia and thrombosis syndrome who presented with recurrent neurologic deficits secondary to severe carotid stenosis. Argatroban anticoagulation was used for the carotid stent deployment. We also present laboratory data that document effective procedural anticoagulation.
Get full access to this article
View all access options for this article.
References
1.
Kelton JG, Smith IW, Warkentin TE, et al: Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood83:3232-3239, 1994.
2.
Greinacher A. , Poetzsch B., Amiral J., et al: Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost71:247-251, 1994.
3.
Visentin GP, Ford SE, Scott JP, et al: Antibodies from patients with heparin-induced thrombocytopenia/ thrombosis are specific for platelet factor 4 complexes with heparin or heparin bound endothelial cells. J Clin Invest93:81-88, 1994.
4.
Gueinadheu A. , Liebenhoff U., Kiefel V., et al: Heparin-associated thrombocytopenia: The effects of various intravenous IgG preparations on antibody mediated plated activation. A possible new indication for high dose IV IgG. Thromb Haemost71:641-645, 1994.
5.
Amiral J., Bridey E., Dreyfus M., et al: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost68:95-96, 1992.
6.
Adelman B., Sobel M., Fujimura Y., et al: Heparin-associated thrombocytopenia; observations on the mechanism of platelet aggregation. J Lab Clin Med113:204-210, 1989.
7.
Kelton JG, Sheridan D., Santos A., et al: Heparin-induced thrombocytopenia: Laboratory studies. Blood72:925-930, 1988.
8.
Chong BH, Castaldi PA, Berndt M.: Heparin-induced thrombocytopenia: Effects of rabbit IgG and FAB and FC fragments on antibody-heparin-platelet interaction. Thromb Res55:291-295, 1989.
9.
Warkentin TE , Levine MN, Hirsh J., et al: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin . N Engl J Med332:1330-1335, 1995 .
10.
Walls JT, Curtis JJ, Silver D., et al: Heparin-induced thrombocytopenia in patients who undergo open heart surgery. Surgery108:686-693, 1990.
11.
Wallis DE, Lewis BE, Pifarre R., et al: Active surveillance for heparin-induced thrombocytopenia on thromboembolism. Chest106:1205, 1994.
12.
Magnani HN: Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaron (Org 10172). Thromb Haemost70:554-561, 1993.
13.
King DE, Kelton JG: Heparin-induced thrombocytopenia. Ann Intern Med100:535-540, 1984.
14.
Becker PS, Miller VT: Heparin-induced thrombocytopenia. Stroke20:1149-1159, 1989.
15.
Warkentin, Theodore : Heparin-induced thrombocytopenia : IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev10:249-258, 1995.
16.
Laster J., Elfrink R., Silver D.: Reexposure to heparin of patients with heparin-associated antibodies . J Vasc Surg9:677-682, 1989.
17.
Schiele F., Villemenot A., Kramarz P., et al: Use of recombinant Hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol50:20-25, 1995.
18.
Chamberlin JR, Lewis B., Leya F., et al: Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol11:511-514, 1995.
19.
Matsuo T., Kario K., Chikahira Y., et al: Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol82:627-629, 1992.
20.
Yadar SS, Roubin GS, Iyer SS, et al: Percutaneous treatment of extracranial carotid atherosclerotic disease with balloon-expandable stent placement. Circulation8:23, 1995.
21.
Shawl FA, Efstratiou A., Hoff S., et al: Combined percutaneous carotid stenting and coronary angioplasty during acute ischemic neurologic and coronary syndromes. Am J Cardiol77:1109-1112, 1996.
22.
Lewis BE, Ferguson JJ, Grassman ED, et al: Successful coronary interventions performed with argatroban in patients with heparin-induced thrombocytopenia and thrombosis syndrome . J Inv Cardiol8 (9) :410-417, 1996.
23.
Hijikata A. , Okamoto S.: In vivo and in vitro studies of a new series of synthetic thrombin inhibitors (abstract). Thromb Res (suppl) 8:83, 1976.
24.
Kikumoto R. , Tamao Y., Ohkubo K., et al: Thrombin inhibitors: 2. Amide derivatives on N alpha-substituted L-arginine. J Med Chem23:830-836, 1980.
25.
Okamato S., Hijikata A.: Potent inhibition of thrombin by a newly synthesized arginine derivative no. 805. The importance of stereostructures of its hydrophobic carboxamide portion . Biochem Biophys Res Commun101:440-446, 1981.
26.
Nagasawg H. : Phase one study of synthetic antithrombin agent (MD-805) (abstract). Jpn J Clin Pharmacol Ther12:359, 1981.
27.
Dougherty KG , Marsh KC, Edelman SK, et al: Relationship between procedural activated clotting time and in-hospital post-PTCA outcome (abstract). Circulation82:III-189, 1990 .
